189 related articles for article (PubMed ID: 37533102)
1. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.
Bastin J; Sroussi M; Nemazanyy I; Laurent-Puig P; Mouillet-Richard S; Djouadi F
J Transl Med; 2023 Aug; 21(1):522. PubMed ID: 37533102
[TBL] [Abstract][Full Text] [Related]
2. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
[TBL] [Abstract][Full Text] [Related]
3. A Gene Signature Derived from the Loss of CDKN1A (p21) Is Associated with CMS4 Colorectal Cancer.
Bueno-Fortes S; Muenzner JK; Berral-Gonzalez A; Hampel C; Lindner P; Berninger A; Huebner K; Kunze P; Bäuerle T; Erlenbach-Wuensch K; Sánchez-Santos JM; Hartmann A; De Las Rivas J; Schneider-Stock R
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008299
[TBL] [Abstract][Full Text] [Related]
4. Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
Källberg J; Harrison A; March V; Bērziņa S; Nemazanyy I; Kepp O; Kroemer G; Mouillet-Richard S; Laurent-Puig P; Taly V; Xiao W
Cell Death Dis; 2023 May; 14(5):306. PubMed ID: 37142595
[TBL] [Abstract][Full Text] [Related]
5. Depletion of mitochondrial reactive oxygen species downregulates epithelial-to-mesenchymal transition in cervical cancer cells.
Shagieva G; Domnina L; Makarevich O; Chernyak B; Skulachev V; Dugina V
Oncotarget; 2017 Jan; 8(3):4901-4913. PubMed ID: 27902484
[TBL] [Abstract][Full Text] [Related]
6. Redox regulation by SOD2 modulates colorectal cancer tumorigenesis through AMPK-mediated energy metabolism.
Zhou C; Lyu LH; Miao HK; Bahr T; Zhang QY; Liang T; Zhou HB; Chen GR; Bai Y
Mol Carcinog; 2020 May; 59(5):545-556. PubMed ID: 32149414
[TBL] [Abstract][Full Text] [Related]
7. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.
Deng J; Tian AL; Pan H; Sauvat A; Leduc M; Liu P; Zhao L; Zhang S; Chen H; Taly V; Laurent-Puig P; Senovilla L; Li Y; Kroemer G; Kepp O
Cell Death Dis; 2021 Oct; 12(11):978. PubMed ID: 34675191
[TBL] [Abstract][Full Text] [Related]
8. Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.
Buikhuisen JY; Gomez Barila PM; Cameron K; Suijkerbuijk SJE; Lieftink C; di Franco S; Krotenberg Garcia A; Uceda Castro R; Lenos KJ; Nijman LE; Torang A; Longobardi C; de Jong JH; Dekker D; Stassi G; Vermeulen L; Beijersbergen RL; van Rheenen J; Huveneers S; Medema JP
J Exp Clin Cancer Res; 2023 Mar; 42(1):56. PubMed ID: 36869386
[TBL] [Abstract][Full Text] [Related]
9. SIRT3-Mediated SOD2 and PGC-1α Contribute to Chemoresistance in Colorectal Cancer Cells.
Paku M; Haraguchi N; Takeda M; Fujino S; Ogino T; Takahashi H; Miyoshi N; Uemura M; Mizushima T; Yamamoto H; Doki Y; Eguchi H
Ann Surg Oncol; 2021 Aug; 28(8):4720-4732. PubMed ID: 33393034
[TBL] [Abstract][Full Text] [Related]
10. SphK1 modulates cell migration and EMT-related marker expression by regulating the expression of p-FAK in colorectal cancer cells.
Xu CY; Liu SQ; Qin MB; Zhuge CF; Qin L; Qin N; Lai MY; Huang JA
Int J Mol Med; 2017 May; 39(5):1277-1284. PubMed ID: 28405684
[TBL] [Abstract][Full Text] [Related]
11. The potential role of platelets in the consensus molecular subtypes of colorectal cancer.
Lam M; Roszik J; Kanikarla-Marie P; Davis JS; Morris J; Kopetz S; Menter DG
Cancer Metastasis Rev; 2017 Jun; 36(2):273-288. PubMed ID: 28681242
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
[No Abstract] [Full Text] [Related]
13. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
14. High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype.
Huang Y; Wang G; Zhao C; Geng R; Zhang S; Wang W; Chen J; Liu H; Wang X
Dis Markers; 2019; 2019():5231269. PubMed ID: 30956730
[TBL] [Abstract][Full Text] [Related]
15. High SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma.
Hou Y; Wang W; Zeng Z; Gan W; Lv S; Li T; Yan Z; Zhang R; Yang M
Aging (Albany NY); 2020 Nov; 12(21):21992-22018. PubMed ID: 33177246
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol regulates mitochondrial reactive oxygen species homeostasis through Sirt3 signaling pathway in human vascular endothelial cells.
Zhou X; Chen M; Zeng X; Yang J; Deng H; Yi L; Mi MT
Cell Death Dis; 2014 Dec; 5(12):e1576. PubMed ID: 25522270
[TBL] [Abstract][Full Text] [Related]
17. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
[TBL] [Abstract][Full Text] [Related]
19. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
